The White House in spring, Washington DC

With spring in the air and the clock rapidly running down on the annual meeting of the American Association for Cancer Research (AACR) in Washington DC in just two weeks time, it’s time to take a look at the seventh topic in our Preview series.

What’s hot on deck to day?

With increasing competition in the metastatic breast cancer space, particularly in HR+ HER2- disease, it’s time to explore key issues around CDK4/6 inhibitors as there’s a lot going on here, including some important presentations ahead.

A road map of what to expect and what to watch out for is often valuable if you want to avoid surprises.

We also examine key issues the companies here are facing as well as highlighting emerging scientific and clinical data of note on several relevant fronts.

To learn more, subscribers can log in

This content is restricted to subscribers

Posted by